Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial

Abstract

In light of the excellent locoregional control rates achieved with CC-IMRT and its acceptable toxicity profile as confirmed by functional assessments and patient-reported outcomes, CC-IMRT may be preferred over IMRT alone.